Estimating the Social Value Generated by Immunotherapy for Renal Cell Carcinoma Patients
Estimating the Social Value Generated by Immunotherapy for Renal Cell Carcinoma Patients Abstract...
Read More
Kidney Cancer Journal
Effects of pazopanib (PAZ) and sunitinib (SUN) dose modifi cation on safety and effi cacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ
Effects of pazopanib (PAZ) and sunitinib (SUN) dose modifi cation on safety and effi cacy in...
Read More
Do CT perfusion measures differ in primary renal tumors versus metastatic lesions in patients receiving treatment for advanced renal cell carcinoma?
Do CT perfusion measures differ in primary renal tumors versus metastatic lesions in patients...
Read More
Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective Experience
Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective...
Read More
DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo controlled trial.
DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib...
Read MoreExercise & Wellness
Mark A. Moyad, MD, MPH
University of Michigan
Ann Arbor, Michigan